Etoposide
As of the edition of 20 October 2026, Etoposide is a small molecule: marketed, first approved in 1980 (CH); acts on TOP2A and TOP2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Vepesid
- First approved
- 9 July 1980 (CH)
- Approvals on record
- 17 in 6 regions
- Holder of the most recent approval
- Avyxa; 8 holders in all
- Registered trials
- 1,270, 167 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Infections; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Etoposide.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 49 | 22 | 9 | 5 |
| Phase 1 | 190 | 108 | 28 | 44 |
| Phase 2 | 732 | 364 | 164 | 98 |
| Phase 3 | 284 | 138 | 62 | 20 |
| Phase 4 | 15 | 3 | 3 | 0 |
| All trials | 1,270 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Earlier holder | 1983 to now |
| Cheplapharm Arzneimittel | Applicant | 1984 to now |
| Corden Pharma Latina | Acquired holder | 2012 to now |
| Onesource Specialty | Acquired holder | 2025 to now |
| Avyxa | Later holder | 2026 to now |
| Nippon Kayaku | Applicant |